In 2023, Sarepta Therapeutics completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), and Scope 2 (indirect emissions from purchased energy).
However, Sarepta Therapeutics has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
In 2023, the total operational greenhouse gas (GHG) emissions of Sarepta Therapeutics amounted to 8,428 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Sarepta Therapeutics increased by 12.52%, suggesting that the company faced challenges in reducing its emissions from its core operations.
In 2023, the total Scope 1 emissions of Sarepta Therapeutics were 3,428 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Compared to the previous year (2022), Sarepta Therapeutics's Scope 1 emissions increased by 26.92%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.
In 2023, Sarepta Therapeutics reported Scope 2 greenhouse gas (GHG) emissions of 5,000 tCOâ‚‚e without specifying the calculation method.
Compared to the previous year (2022), Sarepta Therapeutics's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Sarepta Therapeutics 's emissions have plateaued with no significant change in its energy consumption footprint.
In 2023, Sarepta Therapeutics reported its Scope 2 emissions using an unspecified methodology.